NCT06897215View on ClinicalTrials.gov

A Sequential Cohort Study Exploring GELCLAIR in the Management of Oral Mucositis in Patients Receiving Radical Radiation for Head and Neck Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Oral Mucositis Due to Radiation
Interventions
DEVICE

Hyaluronic acid hydrogel

Assigned to the Experimental Cohort once OM grade 2.0 presents, Gelclair is a hyaluronic acid hydrogel that acts as a protective film in the management of OM. This product is used internationally and has been recently approved by Health Canada as a Class 2 Medical Device with an indication to manage the symptoms of OM caused by radiotherapy and chemotherapy.

All Listed Sponsors
lead

Nova Scotia Health Authority

OTHER

NCT06897215 - A Sequential Cohort Study Exploring GELCLAIR in the Management of Oral Mucositis in Patients Receiving Radical Radiation for Head and Neck Cancer | Biotech Hunter | Biotech Hunter